Get started
Cidara Therapeutics, Inc.Cidara Therapeutics, Inc.Cidara Therapeutics, Inc.

Cidara Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

CDTX chart


Full chart

CDTX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪106.55 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−25.55 USD
Net income (FY)
‪−22.93 M‬ USD
Revenue (FY)
‪63.91 M‬ USD
Shares float
‪5.44 M‬
Beta (1Y)
0.73

Employees


Employees (FY)
69
Change (1Y)
−4 −5.48%
Revenue / Employee (1Y)
‪926.16 K‬ USD
Net income / Employee (1Y)
‪−332.33 K‬ USD

About Cidara Therapeutics, Inc.


Sector
Health Technology
CEO
Jeffrey L. Stein
Headquarters
San Diego
Website
cidara.com
Founded
2012
FIGI
BBG006R5MFT6
Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases. Its product pipeline includes Rezafungin Acetate and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

CDTX news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of CDTX is 19.49 USD — it has decreased by −3.26% in the past 24 hours. Watch Cidara Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cidara Therapeutics, Inc. stocks are traded under the ticker CDTX.
CDTX stock has risen by 13.60% compared to the previous week, the month change is a 31.59% rise, over the last year Cidara Therapeutics, Inc. has showed a 35.14% increase.
We've gathered analysts' opinions on Cidara Therapeutics, Inc. future price: according to them, CDTX price has a max estimate of 33.00 USD and a min estimate of 24.00 USD. Watch CDTX chart and read a more detailed Cidara Therapeutics, Inc. stock forecast: see what analysts think of Cidara Therapeutics, Inc. and suggest that you do with its stocks.
CDTX reached its all-time high on Apr 15, 2015 with the price of 382.60 USD, and its all-time low was 8.00 USD and was reached on Jun 6, 2022. View more price dynamics on CDTX chart.
See other stocks reaching their highest and lowest prices.
CDTX stock is 26.68% volatile and has beta coefficient of 0.73. Track Cidara Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Cidara Therapeutics, Inc. there?
Today Cidara Therapeutics, Inc. has the market capitalization of ‪106.55 M‬, it has increased by 4.42% over the last week.
Yes, you can track Cidara Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Cidara Therapeutics, Inc. is going to release the next earnings report on Mar 11, 2025. Keep track of upcoming events with our Earnings Calendar.
CDTX earnings for the last quarter are −2.45 USD per share, whereas the estimation was −4.25 USD resulting in a 42.35% surprise. The estimated earnings for the next quarter are −3.70 USD per share. See more details about Cidara Therapeutics, Inc. earnings.
Cidara Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of ‪433.33 K‬ USD. In the next quarter, revenue is expected to reach ‪300.00 K‬ USD.
CDTX net income for the last quarter is ‪−15.98 M‬ USD, while the quarter before that showed ‪−89.41 M‬ USD of net income which accounts for 82.12% change. Track more Cidara Therapeutics, Inc. financial stats to get the full picture.
No, CDTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 69.00 employees. See our rating of the largest employees — is Cidara Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Cidara Therapeutics, Inc. EBITDA is ‪−45.05 M‬ USD, and current EBITDA margin is −38.13%. See more stats in Cidara Therapeutics, Inc. financial statements.
Like other stocks, CDTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cidara Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cidara Therapeutics, Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cidara Therapeutics, Inc. stock shows the buy signal. See more of Cidara Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.